Recent trading patterns for Akba stock forecast reflect increased volatility, largely due to sector-wide shifts in biotech valuations. EMA crossovers point toward a bullish trend, though sentiment remains sensitive to clinical trial updates and regulatory announcements. Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener. In the past 30 days, loss estimates for 2024 for Arcturus Therapeutics have improved from $4.39 per share to $2.60 per share. Estimates for 2025 have improved from a loss of 45 cents per share to earnings of 21 cents per share. Year to date, shares of Arcturus Therapeutics have declined 30.3%. Options activity tied to Akba stock forecast has ticked up, with call contracts showing open interest at strike prices above $1.